Scribe Therapeutics SCTX

Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Biotechnology nearest Scribe Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
SCTXScribe Therapeutics	$291.6M	n/m	n/a		n/m	n/m	n/m
PLXProtalix BioTherapeutics	$205.5M	11.1×	34.2×		2.5×	+30%	23.5%
MGTXMeiraGTx	$884.6M	13.0×	18.0×		2.2×	n/m	19.9%
VCELVericel	$2.2B	92.5×	158×		7.1×	+23%	7.9%
ADMAAdma Biologics	$2.4B	15.3×	21.5×		4.7×	+8%	33.0%
Peer median	$1.5B	14.1×	27.8×		3.6×	+23%	21.7%

Each number over time

• Revenue
• EPS
• Shares outstanding

Its groups

• Biotechnology
• Healthcare

Industry

Biotechnology

Sector

Healthcare